StamatiadisD., PapaioannouM.G., Giamarellos-BourboulisE.J., MarinakiS., GiamarellouH., StathakisC.P.Pharmacokinetics of teicoplanin in patients undergoing continuous ambulatory peritoneal dialysis.Perit Dial Int2003; 23: 127–31.
3.
FinchR.C., HollidayA.P., InnesA., BurdenR.P., MorganA.G., ShawP.N.Pharmacokinetic behavior of intraperitoneal teicoplanin during treatment of peritonitis complicating continuous ambulatory peritoneal dialysis.Antimicrob agents Chemother1996; 40: 1971–2.
4.
LupoA., RugiuC., BernichP., LaudonA., MarcantoniC., MosconiG.A prospective, randomized trial of two antibiotic regimens in the treatment of peritonitis in CAPD patients: teicoplanin plus tobramycin versus cephalothin plus tobramycin.J Antimicrob Chemother1997; 40: 729–32.
5.
SchaeferF., KlausG., Müller-WiefelD.E., MehlsO.Intermittent versus continuous intraperitoneal glycopeptide/ ceftazidime treatment in children with peritoneal dialysis–associated peritonitis.J Am Soc Nephrol1999; 10: 136–45.
